These data also support the ongoing phase III multicenter, randomized study of APR-246 in combination with 5-AZA versus 5-AZA alone in patients with TP53-mutant MDS (NCT03745716) (195). The gene discussed is TP53; the disease is myelodysplastic syndrome.